File:Skull and crossbones darktextred2.png

Fatal overdose may occur when opiates are combined with other depressants such as benzodiazepines, barbiturates, gabapentinoids, thienodiazepines, alcohol or other GABAergic substances.

It is strongly discouraged to combine these substances, particularly in common to heavy doses.

Summary sheet: O-Desmethyltramadol

{{#arraydefine: InhaledDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: InhaledDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SmokedDosage | Threshold;< x mg, Light;x - x mg, Common;x - x mg, Strong;x - x mg, Heavy;> x mg }} {{#arraydefine: SmokedDuration | Total;x minutes, Onset;x seconds, Come up;, Peak;x minutes, Offset;x hours, After effects;x hours }} {{#arraydefine: OralDosage | Threshold;Oral threshold dose::5Oral dose units::mg, Light;Oral min light dose::10 - Oral max light dose::25 mg, Common;Oral min common dose::25 - Oral max common dose::50 mg, Strong;Oral min strong dose::50 - Oral max strong dose::100 mg, Heavy;Oral heavy dose::100 mg + }} {{#arraydefine: OralDuration | Total;Oral min total time::6 - Oral max total time::10Oral total time units::hours, Onset;Oral min onset time::20 - Oral max onset time::40Oral onset time units::minutes, Come up;Oral min comeup time::30 - Oral max comeup time::40Oral comeup time units::minutes, Peak;Oral min peak time::2 - Oral max peak time::5Oral peak time units::hours, Offset;Oral min offset time::2 - Oral max offset time::4Oral offset time units::hours, After effects;Oral min afterglow time::1 - Oral max afterglow time::3Oral afterglow time units::hours }} {{#arraydefine: SublingualDosage | Threshold;Sublingual threshold dose::5Sublingual dose units::mg, Light;Sublingual min light dose::10 - Sublingual max light dose::25 mg, Common;Sublingual min common dose::25 - Sublingual max common dose::50 mg, Strong;Sublingual min strong dose::50 - Sublingual max strong dose::80 mg, Heavy;Sublingual heavy dose::80 mg + }} {{#arraydefine: SublingualDuration | Total;Sublingual min total time::5 - Sublingual max total time::10Sublingual total time units::hours, Onset;Sublingual min onset time::20 - Sublingual max onset time::40Sublingual onset time units::minutes, Come up;, Peak;Sublingual min peak time::2 - Sublingual max peak time::5Sublingual peak time units::hours, Offset;Sublingual min offset time::2 - Sublingual max offset time::4Sublingual offset time units::hours, After effects;Sublingual min afterglow time::1 - Sublingual max afterglow time::3Sublingual afterglow time units::hours }} {{#arraydefine: BuccalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: BuccalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: InsufflatedDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: InsufflatedDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: RectalDosage | Threshold;Rectal threshold dose::5Rectal dose units::mg, Light;Rectal min light dose::10 - Rectal max light dose::25 mg, Common;Rectal min common dose::25 - Rectal max common dose::50 mg, Strong;Rectal min strong dose::50 - Rectal max strong dose::80 mg, Heavy;Rectal heavy dose::80 mg + }} {{#arraydefine: RectalDuration | Total;Rectal min total time::4 - Rectal max total time::8Rectal total time units::hours, Onset;Rectal min onset time::3 - Rectal max onset time::5Rectal onset time units::minutes, Come up;Oral min comeup time::8 - Oral max comeup time::10Oral comeup time units::minutes, Peak;Rectal min peak time::3 - Rectal max peak time::5Rectal peak time units::hours, Offset;Rectal min offset time::1 - Rectal max offset time::3Rectal offset time units::hours, After effects;Rectal min afterglow time::1 - Rectal max afterglow time::3Rectal afterglow time units::minutes }} {{#arraydefine: TransdermalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: TransdermalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SubcutaneousDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: SubcutaneousDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: IntramuscularDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: IntramuscularDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: IntravenousDosage | Threshold;Intravenous threshold dose::5Intravenous dose units::mg, Light;Intravenous min light dose::5 - Intravenous max light dose::12.5mg, Common;Intravenous min common dose::12.5 - Intravenous max common dose::25mg, Strong;Intravenous min strong dose::25 - Intravenous max strong dose::50mg, Heavy;Intravenous heavy dose::50mg + }} {{#arraydefine: IntravenousDuration | Total;Intravenous min total time::5 - Intravenous max total time::8Intravenous total time units::hours, Onset;Intravenous min onset time::10 - Intravenous max onset time::15Intravenous onset time units::seconds, Come up;, Peak;Intravenous min peak time::2 - Intravenous max peak time::5Intravenous peak time units::hours, Offset;Intravenous min offset time::2 - Intravenous max offset time::4Intravenous offset time units::hours, After effects;Intravenous min afterglow time::1 - Intravenous max afterglow time::3Intravenous afterglow time units::hours }} {{#arraydefine: uncertaininteractions | {{#ask:O-Desmethyltramadol |?UncertainInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arraydefine: unsafeinteractions | {{#ask:O-Desmethyltramadol |?UnsafeInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arraydefine: dangerousinteractions | {{#ask:O-Desmethyltramadol |?DangerousInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arrayprint:uncertaininteractions||@@@@| }} {{#arrayprint:unsafeinteractions||@@@@| }} {{#arrayprint:dangerousinteractions||@@@@| }}

O-Desmethyltramadol
File:O-Desmethyltramadol (Racemate).svg
Chemical Nomenclature
Common names	common name::O-Desmethyltramadol
Substitutive name	O-DSMT
Systematic name	3-(2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol
Class Membership
Psychoactive class	psychoactive class::Opioid
Chemical class	chemical class::Phenylpropylamine
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. {{#arrayunique: OralDosage}} {{#loop: i | 0 | {{#arraysize: OralDosage}} | {{#arraydefine: val | {{#arrayindex: OralDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: OralDuration}} {{#loop: i | 0 | {{#arraysize: OralDuration}} | {{#arraydefine: val | {{#arrayindex: OralDuration | {{#var: i}} }} | ; }} }} ⇣ Oral Dosage [[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} Duration [[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} {{#arrayunique: SublingualDosage}} {{#loop: i | 0 | {{#arraysize: SublingualDosage}} | {{#arraydefine: val | {{#arrayindex: SublingualDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: SublingualDuration}} {{#loop: i | 0 | {{#arraysize: SublingualDuration}} | {{#arraydefine: val | {{#arrayindex: SublingualDuration | {{#var: i}} }} | ; }} }} ⇣ Sublingual Dosage [[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} Duration [[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} {{#arrayunique: RectalDosage}} {{#loop: i | 0 | {{#arraysize: RectalDosage}} | {{#arraydefine: val | {{#arrayindex: RectalDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: RectalDuration}} {{#loop: i | 0 | {{#arraysize: RectalDuration}} | {{#arraydefine: val | {{#arrayindex: RectalDuration | {{#var: i}} }} | ; }} }} ⇣ Rectal Dosage [[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} Duration [[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} {{#arrayunique: IntravenousDosage}} {{#loop: i | 0 | {{#arraysize: IntravenousDosage}} | {{#arraydefine: val | {{#arrayindex: IntravenousDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: IntravenousDuration}} {{#loop: i | 0 | {{#arraysize: IntravenousDuration}} | {{#arraydefine: val | {{#arrayindex: IntravenousDuration | {{#var: i}} }} | ; }} }} ⇣ Intravenous Dosage [[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} Duration [[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions
@@@@
@@@@
@@@@

O-Desmethyltramadol (also known as O-DSMT and desmetramadol) is an psychoactive class::opioid substance of the chemical class::phenylpropylamine class. It is an active metabolite of tramadol.

O-DSMT has no documented history of human use before it appeared for sale on the research chemical market in the 2010s.

Subjective effects include sedation, pain relief, anxiety suppression, muscle relaxation, and euphoria. In comparison to tramadol, O-DSMT is reported to be less stimulating and feels considerably closer to a traditional opiate. Being the metabolite that is mainly responsible for the analgesic effect of tramadol, O-DSMT is significantly more potent by weight than its parent compound.

O-DSMT has a very short history of human use and not much is known about its toxicity and abuse potential. However a human clinical trial in 2019 ascertained that O-DSMT shares tramadol's safety profile when used in (low) therapeutic dosages. It is highly advised to use harm reduction practices if using this substance.

Chemistry

(+/-)O-Desmethyltramadol, or 3-(2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol, is an atypical synthetic opioid. O-Desmethyltramadol is loosely analogous to codeine, but is not a morphinan opiate. Instead, it contains two rings including a cyclohexane ring that is bonded to a phenyl ring at R₁. This phenyl ring is substituted at R₃ with a hydroxy group (OH-). An additional hydroxy group is found at the same location the cyclohexane ring is bonded to at the phenyl ring, R₁. O-DMST features a third substitution on its cyclohexane ring at R₂. Here the ring is bonded to a dimethylamine group connected through a methylene bridge.

O-Desmethyltramadol is atypical as it is found in a racemate (combination) of its stereoisomers. Stereoisomers are two molecules that share the same chemical structure, but are three-dimensional mirror images of each other. Tramadol is produced as a racemate of its two isomers because the combination is proven to be more effective. Flipping the direction of the R₂ and R₁ bonds results in the R- and S- enantiomers of O-Desmethyltramadol. O-DMST is nearly identical to tramadol, and is named for the lack of the methyl group of tramadol's R₃ methoxy substituion.

Pharmacology

O-DSMT is considerably more potent as a μ-opioid agonist compared to tramadol. Additionally, unlike tramadol, it is a high-affinity ligand of the δ- and κ-opioid receptors.

The two enantiomers of O-DSMT show quite distinct pharmacological profiles; both (+) and (−)-O-DSMT are inactive as serotonin reuptake inhibitors, but (−)-O-DSMT retains activity as a norepinephrine reuptake inhibitor, and so the mix of both the parent compound and metabolites contributes significantly to the complex pharmacological profile of tramadol. While the multiple receptor targets can be beneficial in the treatment of pain (especially complex pain syndromes such as neuropathic pain), it increases the potential for drug interactions compared to other opioids, and may also contribute to side effects.

Opioids exert their effects by binding to and activating the μ-opioid receptor. This occurs because opioids structurally mimic endogenous endorphins which are naturally found within the body and also work upon the μ-opioid receptor set. The way in which opioids structurally mimic these natural endorphins results in their euphoria, pain relief and anxiolytic effects. This is because endorphins are responsible for reducing pain, causing sleepiness, and feelings of pleasure. They can be released in response to pain, strenuous exercise, orgasm, or general excitement.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

{{

 #fornumargs: number
 | column
 | 

{{#var: column}} }}

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

• Erowid Experience Vaults: O-Desmethyltramadol

Toxicity and harm potential

Further information: Research chemicals § Toxicity and harm potential

O-DSMT has a Toxicity::moderate potential toxicity relative to its dose due to its potency. As with all opioids, long-term effects can vary but can include diminished libido, apathy and memory loss. It is also [[Toxicity::potentially lethal when mixed with depressants like alcohol or benzodiazepines]].

O-DSMT has recently been marketed as a currently legal substitute for illegal opioid drugs, either in powder form or mixed into various other preparations. One such blend was sold under the brand Krypton and contains powdered kratom leaf (Mitragyna speciosa) laced with O-DSMT and was reportedly linked to at least 9 accidental deaths from overdose during 2010–2011.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other opioids, the chronic use of O-DSMT can be considered Addiction potential::moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal symptoms may occur if a person suddenly stops their usage.

Tolerance to many of the effects of O-DSMT Time to full tolerance::develops with prolonged and repeated use. The rate at which this occurs develops at different rates for different effects, with tolerance to the constipation-inducing effects developing particularly slowly for instance. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about Time to half tolerance::3 - 7 days for the tolerance to be reduced to half and Time to zero tolerance::1 - 2 weeks to be back at baseline (in the absence of further consumption). O-DSMT presents cross-tolerance with [[Cross-tolerance::all other opioids]], meaning that after the consumption of O-DSMT all opioids will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

• DangerousInteraction::Alcohol - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. Place affected patients in the recovery position to prevent vomit aspiration from excess. Memory blackouts are likely
• UncertainInteraction::Stimulants - Stimulants increase respiration rate which allows for a higher dose of opiates than would otherwise be used. If the stimulant wears off first then the opiate may overcome the user and cause respiratory arrest.
• DangerousInteraction::Benzodiazepines - Central nervous system and/or respiratory-depressant effects may be additively or synergistically present. The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position blackouts/memory loss likely.
• DangerousInteraction::DXM - Generally considered to be toxic. CNS depression, difficulty breathing, heart issues, and liver toxicity have been observed. Additionally if one takes DXM, their tolerance of opiates goes down slightly, thus causing additional synergistic effects.
• DangerousInteraction::GHB/DangerousInteraction::GBL - The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position
• DangerousInteraction::Ketamine - Both substances bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
• UncertainInteraction::MAOIs - Coadministration of monoamine oxidase inhibitors (MAOIs) with certain opioids has been associated with rare reports of severe adverse reactions. There appear to be two types of interaction, an excitatory and a depressive one. Symptoms of the excitatory reaction may include agitation, headache, diaphoresis, hyperpyrexia, flushing, shivering, myoclonus, rigidity, tremor, diarrhea, hypertension, tachycardia, seizures, and coma. Death has occurred in some cases.
• DangerousInteraction::MXE - MXE can potentiate the effects of opioids but also increases the risk of respiratory depression and organ toxicity.
• UncertainInteraction::Nitrous - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. While unconscious, vomit aspiration is a risk if not placed in the recovery position. Memory blackouts are common.
• UncertainInteraction::PCP - PCP may reduce opioid tolerance, increasing the risk of overdose.
• DangerousInteraction::Tramadol - Increased risk of seizures. Tramadol itself is known to induce seizures and it may have additive effects on seizure threshold with other opioids. Central nervous system- and/or respiratory-depressant effects may be additively or synergistically present.
• DangerousInteraction::Grapefruit - While grapefruit is not psychoactive, it may affect the metabolism of certain opioids. Certain opioids such as oxycodone and fentanyl primarily metabolized by the enzyme CYP3A4, which is potently inhibited by grapefruit juice. This may cause the drug to take longer to clear from the body. it may increase toxicity with repeated doses. Methadone may also be affected. Codeine, hydrocodone, and Tramadol are metabolized by CYP2D6. People who are on medicines that inhibit CYP2D6, or that lack the enzyme due to a genetic mutation will not respond to codeine as it can not be metabolized into its active product: morphine.

Serotonin syndrome risk

Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.

• DangerousInteraction::MAOIs - Such as banisteriopsis caapi, syrian rue, phenelzine, selegiline, and moclobemide.
• DangerousInteraction::Serotonin releasers - Such as MDMA, 4-FA, methamphetamine, methylone and αMT.
• DangerousInteraction::SSRIs - Such as citalopram and sertraline
• [[Wikipedia:SNRIs|DangerousInteraction::SNRIs]] - Such as tramadol and venlafaxine
• DangerousInteraction::5-HTP

Legal status

File:Handcuffs-300px.png

This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

There is little information online regarding the international legalities of O-Desmethyltramadol possession but it is confirmed as a controlled substance within the United Kingdom.

• Germany: O-DSMT is not a controlled substance under the BtMG. It is legal, as long as it is not sold for human consumption, according to §2 AMG.
• Sweden: O-DSMT is a controlled substance and considered a narcotic by law.
• Switzerland: O-DSMT is not controlled under Buchstabe A, B, C and D. It could be considered legal.
• United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.

See also

• Responsible use
• Tramadol
• Opioid

External links

• O-Desmethyltramadol (Wikipedia)
• O-Desmethyltramadol (Isomer Design)

References

{{#set:Featured=true}}